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Identification of systemic immune response
markers through metabolomic profiling of plasma
from calves given an intra-nasally delivered
respiratory vaccine
Darren W Gray1*, Michael D Welsh2, Simon Doherty2, Fawad Mansoor2, Olivier P Chevallier1,
Christopher T Elliott1 and Mark H Mooney1
Abstract
Vaccination procedures within the cattle industry are important disease control tools to minimize economic and
welfare burdens associated with respiratory pathogens. However, new vaccine, antigen and carrier technologies are
required to combat emerging viral strains and enhance the efficacy of respiratory vaccines, particularly at the point
of pathogen entry. New technologies, specifically metabolomic profiling, could be applied to identify metabolite
immune-correlates representative of immune protection following vaccination aiding in the design and screening
of vaccine candidates. This study for the first time demonstrates the ability of untargeted UPLC-MS metabolomic
profiling to identify metabolite immune correlates characteristic of immune responses following mucosal vaccination in
calves. Male Holstein Friesian calves were vaccinated with Pfizer Rispoval® PI3 + RSV intranasal vaccine and metabolomic
profiling of post-vaccination plasma revealed 12 metabolites whose peak intensities differed significantly from controls.
Plasma levels of glycocholic acid, N-[(3α,5β,12α)-3,12-Dihydroxy-7,24-dioxocholan-24-yl]glycine, uric acid and biliverdin
were found to be significantly elevated in vaccinated animals following secondary vaccine administration, whereas
hippuric acid significantly decreased. In contrast, significant upregulation of taurodeoxycholic acid and propionylcarnitine
levels were confined to primary vaccine administration. Assessment of such metabolite markers may provide greater
information on the immune pathways stimulated from vaccine formulations and benchmarking early metabolomic
responses to highly immunogenic vaccine formulations could provide a means for rapidly assessing new vaccine
formulations. Furthermore, the identification of metabolic systemic immune response markers which relate to specific
cell signaling pathways of the immune system could allow for targeted vaccine design to stimulate key pathways which
can be assessed at the metabolic level.
Introduction
The vaccination of farm animals against endemic, genetically
evolving and emerging pathogens is important not only to
ensure animal health, but also to reduce the costs associated
with disease losses, either clinical or subclinical. Successful
vaccination leads to the production of specific T and B cell
effector immune responses that assist in the control
of infection within the animal. This results in the
generation of virus neutralizing antibodies that recognize
the pathogen, specific effector T-cell responses and
the development of an immune memory response
helping to protect against future exposure to the infection.
Continuous vaccine development is required to address
virus evolution, new and emerging viral threats and
to improve vaccine efficacy against currently managed
pathogens. However, assessment of new vaccine candidates,
adjuvant and novel vaccine carrier systems (such as
nanoparticles) using animal trials is extremely expensive
and can take several months to years (investigation of
short term immune responses, vaccine-challenge studies
and field trials and long term immune protection
against natural wildtype virus challenge) [1]. Although
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the expenditure associated with animal vaccine develop-
ment is not fully disclosed, the estimated budget required
to develop a single FDA approved vaccine for human
studies is estimated in the region of $1-2 billion [2]. The
majority of these costs are attributed to the high failure
rate of vaccine candidates/formulations, with only 1 in
every 10 000 vaccine formulations gaining approval by the
FDA [3]. New vaccine candidates may initially be assessed
in mice models, however this does not necessarily trans-
late to performance in the target species and animal trials
can have poor efficacy [4] or fail to induce immune
protection at all [5] as a result of species differences
in immune systems [3]. Furthermore, many factors
such: as immune system maturity, vaccine delivery
route, concurrent infections, poor nutrition and the
presence of maternally derived antibodies can affect
vaccine efficacy [6]. As the expenditure associated with
candidate vaccine development escalates with clinical trial
progression, rapid vaccine screening methods which can
assess candidate vaccine effectiveness at early trial stages
in vivo are required to minimize financial outlay and
improve the speed of vaccine development pipelines.
In the agricultural industry the Bovine Respiratory
Disease (BRD) complex is considered to be one of the
most significant causes of economic loss in intensively
reared cattle worldwide. The associated losses accruing
from the elevated mortality and poor growth performance
of infected animals [7] coupled with the need for costly
therapeutic interventions have a significant negative
impact on farm incomes. This disease complex is esti-
mated to result in an annual total economic loss to
the US agri-food industry of over $2 billion, with
treatment and preventative costs approaching $3 billion
[8]. Whilst vaccination against the infectious agents
involved in BRD pathogenesis is currently employed to
manage the disease [9,10], it has not significantly reduced
BRD prevalence or severity. Furthermore, it has been
observed that some animals fail to develop immune pro-
tection despite vaccine treatment, becoming infected with
each new seasonal BRD outbreak [11]. Therefore, the
development of new methods for screening BRD pathogen
vaccine candidates, along with the clear understanding of
the host immune response, would provide significant
economic and animal welfare benefits to the agricultural
industry by speeding up the vaccine development.
Current methods for determining viral vaccine effective-
ness in mammalian species include assessment of neutral-
izing antibody titre [12,13], PCR-based detection of viral
load in infected tissues at post-immunization challenge
[12], expression of pro- and anti-inflammatory cytokines
[13], duration of viral shedding after post-immunization
challenge [14], and mortality/morbidity findings at
post-mortem [15]. However, the quantitative analysis
of pro- and anti-inflammatory cytokines is generally
considered to be one of the important indicators of
vaccine efficacy, but typically only occurs after preliminary
candidate antigen or formulation screening [6], and may
require a number of vaccines and challenge studies to fully
elucidate the important factors associated with a protective
immune response. A greater understanding of not only the
proteomic responses to vaccination [16,17], but also the
changes at the metabolic level in bio-fluids, such as plasma
or serum, may help develop early marker-based screening
tests. These can be used to assess the potential of new
vaccine candidates and also may provide additional infor-
mation to improve the rationale behind future vaccine
approaches taking into account vaccine delivery routes,
vaccine carrier technologies and animal genetics.
Untargeted metabolomic profiling refers to the top
down global analysis of small molecules or “metabolites”
with molecular weights less than 1 kDa and is typically
performed by Nuclear Magnetic Resonance (NMR) or
mass spectrometry (MS) techniques, with the later
offering greater sensitivity. Ultra Performance Liquid
Chromatography (UPLC) coupled to a highly accurate mass
spectrometer allows for the separation and determination
of elemental composition (and hence the identification) of
1000s of metabolites in a single sample. As metabolites are
often end-stage products of biological processes, their
analysis can provide a greater understanding of the
physiological state of an organism at the time of sampling
compared to genomic or proteomic analysis. The applica-
tion of metabolomic techniques to the analysis of bio-fluids
has been found to offer interesting new insights to the
understanding of the physiological processes involved in
disease development and diagnosis [18-21]. However, to
date little emphasis has been placed on assessing the
in vivo metabolomic changes induced by immunization
procedures and foreign antigen exposure.
This study for the first time reports the metabolomic
responses in plasma of calves vaccinated with an intranasal
vaccine (Pfizer Rispoval® PI3 + RSV) composed of the modi-
fied live viruses Bovine Respiratory Syncytial Virus (BRSV)
and Bovine Parainfluenza Virus-3 (BPI3V). BRSV and
BPI3V are two of the major viral pathogens involved in the
Bovine Respiratory Disease (BRD) complex [7]. The aims of
the current study were to identify plasma metabolomic
markers of the primary and secondary immune response in
calves to administration of a commercial intranasal vaccine
containing live modified virus. Importantly, it is well known
that vaccination via the parenteral route leads to poor
protection at mucosal surfaces. Therefore the studies
undertaken here allow vaccine immunology and bio-
markers to be identified through the natural route of infec-
tion for these respiratory viruses in order to identify the
most suitable host defense mechanisms. This is the first
untargeted UPLC-MS based metabolomics study to reveal
metabolite markers of the immune response occurring
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during vaccination which may have potential use in the
early screening of candidate vaccine effectiveness and aid
new vaccine design by increasing the understanding of the
processes involved in immune response development post
vaccination.
Materials and methods
Chemicals and reagents
HPLC grade acetone was purchased from Sigma Aldrich
(Dorset, UK). LC-MS grade acetonitrile, water, methanol
and chloroform were purchased from Fisher Scientific
(Loughborough, UK). All analytical standards for metabol-
ite confirmation were purchased from Sigma Aldrich.
Experimental design and sample collection
All animal studies were carried out in accordance
with the UK Animals (Scientific Procedures) Act 1986
and with the approval of the AFBI Ethical Review
Committee. Figure 1 illustrates the experimental
design and sample collection days throughout the
study. Twelve male Holstein Friesian calves aged
between 20 and 25 weeks were divided into two study
groups (n = 6) and assigned as non-vaccinated or
vaccinated calves. Vaccinated calves were treated with
Pfizer Rispoval® PI3 + RSV intranasal vaccine (designated
vaccinated animals) as per manufacturers instructions,
and non-vaccinated calves were treated with empty
poly(lactic-co-glycolic) acid PLGA nanoparticles (designated
non-vaccinated) prepared using standard double emulsifi-
cation solvent evaporation technique (w/o/w) [22].
Calves were dosed at day 0 and day 35, and screened
weekly for the presence of BPI3V IgG in blood serum using
Svanovir-PI3V-Ab kit (Boehringer Ingelheim Svanovir,
Uppsala, Sweden) as per manufacturer’s instructions. Calves
were sampled at days 0 (pre-dosage), 7, 14, 28 (initial
vaccine dosage), 42, 49 and 63 (booster dosage). One
week after completion of the vaccination study (day
70) all calves were experimentally challenged with
BPI3V through nasal inoculation with 2 mL of virus
suspension (TCID50 of 10
6.78/mL) per nostril. Calves
were sampled at days 70, 75, 82, 84 and 90 (days 0,
5, 12, 14 and 20 post-BPI3V challenge respectively).
Serum was prepared from blood drawn by jugular
venepuncture into 10 mL BD Vacutainer® glass serum
tubes. The blood was allowed to clot at room temperature
for 30 min prior to centrifugation at 2000 g to remove the
clot. Samples were stored at 4 °C prior to analysis. Blood
haematology was monitored weekly during vaccination
stages and at days 70, 75, 82, 84 and 90 (post-BPI3V
challenge stages). Rectal temperatures were taken at
days 14, 28, 42 and 63. Blood was sampled from the
calves by jugular venepuncture into 6 ml plastic K3
EDTA Vacuette tubes (Greiner bio-one, Stroudwater, UK)
and processed to platelet poor plasma by the double
centrifugation method previously described [23]. All
samples were processed at random within 2 h of initial
blood sampling and stored at −80 °C prior to use.
Sample preparation
600 μL of plasma was added to 2.4 mL of ice cold
acetone, vortexed for 30 s and placed on ice for 15 min.
The sample was then deproteinated by centrifugation at
-7 0 7 63492814 82 
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Figure 1 Sampling points for metabolomic profiling of plasma in calves following vaccination and subsequent BPI3V challenge. Male
Holstein Friesian calves were dosed with Pfizer Rispoval®PI3 + RSV intranasal vaccine (vaccinated) or empty PLGA nanoparticles (non-vaccinated) at
day 0. A secondary booster dosage was administered at day 35. At day 70 all animals were experimentally challenged with BPI3V via nasal
inoculation. At day 6 during the BPI3V challenge study 3 calves per group were sacrificed for viral isolation and histology. Sampling points for
metabolomic profiling of plasma are indicated throughout.
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4000 g at 4 °C for 20 min. 2.4 mL of supernatant was
removed and dried under nitrogen for 45 min at 40 °C
using TurboVap LV (Caliper Life Sciences, Hopkinton,
USA). Resulting residue was reconstituted in 500 μL of
Ultra Pure H2O and liquid/liquid extraction of lipids
performed by addition of 500 μL of ice-cold Methanol:
Chloroform (1:1 v/v) and vortexing for 30 s followed by
centrifugation at 16 000 g at 4 °C for 15 min. liquid/
liquid extraction was repeated and after centrifugation
900 μL of the aqueous layer was removed and dried
under nitrogen using TurboVap at 40 °C for 45 min.
The residue was reconstituted in 300 μL Ultra Pure
H2O and filtered by centrifugation at 10 000 g at 4 °C
using 0.22 μm Constar Spin-X® Centrifuge Tube Filter
for 5 min.
UPLC-MS analysis of Bovine Plasma
UPLC-MS analysis was performed using an Acquity
UPLC system coupled to a XEVO G2 Q-TOF (Waters
Corporation, Milford, MA, USA. 8 μL of prepared sam-
ple extracts were injected onto an Acquity UPLC HSS-
T3 C18 column (100 mm × 2.1 mm i.d., 1.8 μm; Waters
Corporation, Milford, MA, USA). Column and autosampler
temperature were maintained at 50 °C and 10 °C re-
spectively. Chromatographic separation was carried
out at a flow rate of 600 μL/min with mobile phase
consisting of 99.9% H2O/0.1% Formic Acid (A) and
99.9% Acetonitrile/0.1% Formic Acid (B). The elution
gradient was as follows: 0–2 min isocratic at 1% of B,
2–14.5 min linear gradient from 1-100% of B, 14.5-17 min
isocratic at 100% of B, 17–17.5 min linear gradient from
100-1% of B and finally 17.5-20 min isocratic at 1% of B.
Mass spectrometry was performed using a Waters XEVO
G2 QTOF operating in positive-ion mode (ESI+) with the
capillary voltage set to 1500 V and the sampling cone
voltage 30 V. The desolvation and cone gas flows were set
at 750 L/h and 100 L/h respectively. Source and desolva-
tion temperatures were 120 °C and 400 °C respectively.
Leucine Enkephalin ([M +H]+= 278.1141 Da, and [M+H] =
556.2771 Da) was used for accurate lockmass calibration
during data acquisition. Lockmass acquisition settings
were: 0.5 s scan time, 30 s interval, 3 scan average, mass
window +/− 0.5 Da. Collision energy was only applied on
function 2, with ramping between 15 V and 30 V and cen-
troid data was acquired using positive-ion, resolution
mode.
Mass spectrometry data processing
Total Ion Count (TIC) chromatograms and spectra were
acquired with MassLynx version 4.1 (Waters) in centroid
format and metabolite data was processed using
MarkerLynx software (Waters Corporation, Milford,
MA, USA). The MarkerLynx method for data extraction
and de-convolution was as follows: Ions were extracted
from function 1 data using peak detection analysis of re-
tention time window 0.30-14.50 min, with a mass range
of 100 Da to 1200 Da. The extracted-ion chromatogram
(XIC) window for data collection was 0.2 Da and apex
peak tracking parameters were set to automatic with no
smoothing. Data collection parameters consisted of an
intensity threshold (counts) of 500 and a mass window of
0.02 Da with a retention time window of 0.20 min. A
noise elimination level of 6 was applied and isotopes were
removed. Peak heights for extracted ions were normalized
against the total peak height of all extracted ions and stan-
dardized to a total ion count of 10 000. The results were
exported in .csv format as a two dimensional data table in
which rows and columns respectively represented ana-
lysed samples and the relative normalized peak heights of
each detected mass spectrometric signal, i.e. as an Accurate
Mass (m/z) and Retention Time (min) Pair (AMRTP).
Data analysis
Temporal changes in BPI3V antibody titre were ana-
lysed using two-tailed paired T-test, and significant
differences between treatment groups at sampling
stages was assessed using two-tailed heteroscedastic
T-test. SIMCA-P+ version 13.0 (Umetrics, Sweden)
was used for multivariate metabolite marker selection.
For SIMCA-P+ analysis, data was prefiltered to exclude
AMRTPs with coefficient of variation greater than 50% in
replicate quality control pools. All centroid data were
Pareto scaled and analysed by unsupervised Principle
Component Analysis (PCA) and supervised discriminatory
analysis by Orthogonal Projections of Latent Structures-
Discriminant Analysis (OPLS-DA). Unsupervised PCA
models were generated at each sampling day to reveal
potential relationships between treatment groups.
Supervised analysis by OPLS-DA was performed to
reveal potential markers of response to treatment in
vaccinated calves compared to non-vaccinated calves
at each sampling day. Robustness of final OPLS-DA
discriminative models was assessed by setting a predictive
model of each case in which 2/3 of the data (known treat-
ment) was used to predict the remaining 1/3 (unknown
treatment).
Identification of potential metabolite markers
The elemental composition of selected parent compounds
was determined in MassLynx using both positive and
negative mode data. Mass uncertainty was set to 3mDa,
odd and even electron state, carbon isotope filter of +/−
5% and elements included were C, H, O, N, P and S.
Where applicable Na and K adduct elemental composition
were determined with the respective element included
in the analysis parameters. Elemental compositions were
searched against PubChem and Chemspider online data-
bases, and where possible Function 2 fragments were
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matched against Metlin, HMDB or Massbank databases.
Where fragmentation spectra for the analyte in question
was not available, in silico fragmentation was performed
using Metfrag and Function 2 fragmentation data was val-
idated against potential in silico fragments. Compounds
revealed by database matching or in silico fragmentation
had their identities confirmed against commercial analyt-
ical standards by UPLC-MS. Pooled plasma samples and
individual standards (1 μM) were analysed under identical
UPLC and mass spectrometric run conditions as utilized
previously, and metabolite identities confirmed by match-
ing retention time and Function 1 and Function 2 spectra
(including low and high energy fragments and adducts).
Results
Haematological and immunological responses to
vaccination
Calves were monitored throughout the study to ensure
normal health status and assess immunological responses
to vaccination. Rectal temperatures taken at days 14, 28,
42 and 63 were within the reference parameters 38.3 to
39.4 °C with no significant differences observed between
study groups (as illustrated in Additional file 1). Serum
was obtained from all calves to determine weekly IgG anti
BPI3V sera titres during vaccination procedures and to
perform routine blood hematology analysis to validate
calve health. The results of BPI3V IgG antibody titre
screening are shown in Figure 2 in addition to lymphocyte
and neutrophil counts obtained from hematology results.
Prior to vaccination no significant differences in the
BPI3V IgG antibody titre between study groups were
observed (Figure 2A). IgG BPI3V antibody titres were
significantly elevated (p < 0.05) in vaccinated calves
compared to non-vaccinated calves at days 14, 49, 56
and 63. The BPI3V IgG antibody titre in vaccinated
calves was shown to increase significantly (p < 0.05)
from days 7 to 14 and significantly (p < 0.05) declined
from day 14 to 28 whilst remaining significantly (p < 0.05)
elevated compared to day 0. On administration of the
second vaccine dosage (day 35) BPI3V IgG antibody
titre increased (p < 0.05) from days 42 to 56, and
remained significantly elevated in the vaccinated study
group relative to non-vaccinated calves until day 63. These
IgG responses indicate that the booster immunization was
necessary to further increase the titres of BPI3V specific
antibodies. Upon BPI3V challenge at day 70, BPI3V IgG
antibody titre was maintained at significantly higher
(p < 0.05) levels at days 70 and 75 in vaccinated calves
compared to non-vaccinated calves indicating an
adaptive primed immune response to infection. There was
an observed drop in BPI3V IgG titre in vaccinated calves
from day 70 to day 75 but this level was still significantly
higher than that found in non-vaccinated calves (p < 0.05).
There were no significant changes in the levels of BPI3V
IgG titre in vaccinated or non-vaccinated calves through-
out the remaining infection stages, with mean BPI3V IgG
titres remaining higher in vaccinated calves compared to
non-vaccinated.
The haematology results are illustrated in Additional
file 1. Red Blood Cell count (RCC), White Blood
Cell count (WCC), Hemoglobin content (HG), Mean
Corpuscular Volume (MCV), Mean Corpuscular
Haemoglobin (MCH), Packed Cell Volume (PCV) and
Platelet count (PLT) measurements for all calves were
within the specified reference parameters based on data
from Brun-Hansen et al. [24] for calves at corresponding
ages which are known to differ from adults. However,
significant differences in lymphocyte and neutrophil count
were observed between study groups at a number of
points throughout the vaccination stages of the study
whilst remaining within reference parameters for healthy
animals. Figure 2B reveals significantly (p < 0.05) higher
lymphocyte counts at day 42 (2 weeks post-booster
immunization) in vaccinated animals compared to non-
vaccinated. Furthermore, lymphocyte counts in vaccinated
animals were found to rise significantly (p < 0.05) from
day 14 to 42 and decreased from day 49 to 63, with no
significant temporal changes observed in non-vaccinated
animals. Figure 2C illustrates that neutrophil counts
were significantly higher at day 0 (p < 0.01) and day
14 (p < 0.05) and significantly lower (p < 0.05) at day
42 in vaccinated compared to non-vaccinated animals.
Neutrophil counts decreased significantly (p < 0.05) in
vaccinated animals from day 14 to 42 and increased
significantly (p < 0.05) in non-vaccinated animals from day
14 to 42. At post-BPI3V challenge stages, WCC, RCC and
lymphocyte counts were outside reference parameters.
There was a significant (p < 0.05) rise in WCC in non-
vaccinated animals after BPI3V infection from days 70 to
day 75 and WCC was higher than reference parameters
from days 75 to 90 in vaccinated calves, and significantly
(p < 0.05) higher at day 90 in vaccinated calves compared
to non-vaccinated. RCC was elevated outside reference
parameters throughout the study and was significantly
(p < 0.05) higher in vaccinated calves at day 75 compared
to non-vaccinated. Whilst No significant differences were
observed in lymphocyte counts between study groups,
lymphocyte counts were above the reference parameters
in both study groups at day 75. There was a significant
increase in lymphocyte counts in non-vaccinated animals
from day 70 to 75 and a significant decrease from days 75
between days 82, with no significant variations observed
in lymphocyte counts of vaccinated animals. There were
no observed significant differences in neutrophil counts
between study groups at corresponding sampling points
post-infection, however, significant (p < 0.05) temporal
variations were observed with a decrease from day 70 to
75 in non-vaccinated animals, and an increase from day
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75 to 82 in both study groups. Despite being within
the reference parameters, significant differences were
observed in PCV at day 75, MCV at day 82 and
MCH at day 75 between study groups.
Selection of metabolomic markers of vaccine response via
multivariate data analysis
Representative Base Peak Intensity (BPI) chromatograms
of plasma from both a vaccinated and non-vaccinated
calf at day 49 are presented in Figure 3. When observing
the acquired chromatograms there is obvious poor
column retention of polar compounds between 1 min
and 2 min. Between 2 min and 14.5 min chromatographic
separation was excellent, with no observable overlapping
peaks and minor differences between the acquired profiles
of respective study groups (e.g. peaks at 5.00 min and
7.73 min) can be determined by visual examination. 3224
features were extracted from raw data using MarkerLynx
and normalized to reduce the effects of batch to batch
variation in subsequent analysis steps. In order to validate
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instrument performance landmark compounds in plasma
(validated using pure standards) were used to analyse
retention time deviation and mass accuracy between
and within batch runs. The retention time deviation
and mass accuracy of L-Phenylalanine, L-Tryptophan
and Glycocholic Acid were determined in inter-run
quality control pools and are presented in Additional file 2.
Mass accuracy was consistent for all markers, with a
maximum deviation of 2.26mDa. The maximum retention
time deviation of peak top time was approximately 6 s.
Maximum retention time deviation was observed with
phenylalanine which can be accounted for by its wider
elution time as illustrated in Figure 3. The excellent reten-
tion time stability and mass accuracy during and between
separate analysis runs provides assurance in accuracy of
the data collected.
Untargeted Principle Component Analysis (PCA) was
performed in SIMCA-P+ v 13. The dataset was filtered to
exclude variables with a coefficient of variation greater
than 50% in replicate quality control pools. PCA models
were constructed from 764 AMRTPs, and further divided
into sub-models by sampling day. Replicate injections
were tightly clustered on the PCA scores plot, indicating
low inter-run variation in peak intensity. No injections
were observed as having d-mox twice d-crit (possible
outliers). The majority of variation explained by principle
components (PC) 1 and 2 was due to variation between
the three analysis runs (48.3 to 57.1%), and therefore for all
stage PCA sub-models only PCs 3 and 4 were investigated.
At days 7, 14, 42 and 49 there was separation on the
PCA-scores plot between study groups when observing the
variation in the data explained by principle components 3
and 4 shown in Figures 4B,C,E and F. Roughly 14 to 20%
of the variation in the dataset was responsible for
group separation in PCs 3 and 4 in substage PCA
models. However, at days 28 and 63 there was a significant
overlap between treatment groups (Figures 4D and G
respectively). When the data from each analysis run
was treated separately to remove run-to-run noise,
group separation was achieved using principle compo-
nents 1 and 2 only. Therefore, the only negative im-
pact of combining data from separate analyses was
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Figure 3 Metabolomic profiling of bovine plasma by positive ionization UPLC-MS. (A) Total Ion Chromatogram (TIC) of bovine plasma.
Peaks relating to L-phenylalanine, L-tryptophan and glycocholic acid are indicated. The percentage of solvent B (99.9% acetonitrile, 0.1% formic
acid) is indicated on right Y axis. (B) BPI chromatograms of plasma from a vaccinated calf at day 49 (two weeks after booster dosage), and (C) BPI
chromatogram of plasma from a non-vaccinated calf at day 49. Representative differences between treatment groups are at the peaks indicated
with retention times 5.00 and 7.73 min.
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that components representing analysis run separation
could be ignored.
OPLS-DA was used for the selection of markers of
immune response to vaccination. In order to validate
OPLS-DA models, 2/3 of the randomly selected data
(4 calves per group) was used to generate OPLS-DA
models, with the remaining 1/3 used as a test set.
The results from cross validation are illustrated in
Additional file 3. At days 7, 14, 42 and 49 constructed
models could accurately predict class allocation for the
test set. At days 28 and 63 there was no correct classifica-
tion for test samples, concurrent with the PCA scores plot
in which there was no separation between study groups.
Therefore, OPLS-DA models were constructed at days 7,
14, 42 and 49 for the selection of potential markers with
all experimental calves used in the generation of these
models. For all models the variables which contributed to
study group discrimination in OPLS-DA models were
selected on the criteria of a variable importance (V.I.P.)
score > 1. The OPLS-DA S-plots of the metabolomic
profiling of plasma from vaccinated and non-vaccinated
calves at days 7, 14, 42 and 49 are illustrated in
Figures 5A-D respectively. Many of the variables which
contributed to the discrimination between study groups
were related low energy fragments or adducts of parent
compounds. 96 AMRTPs which demonstrated significant
variation (p < 0.05, two-tailed heteroscedastic T-test) and a
fold-change (FC) greater than 1.5 between treatment
groups were selected (see Additional file 4). Significant
AMRTPs were filtered to remove those with poorly
consistent peak heights in replicate injections and
high intergroup variability. Fragment ions and adducts
were then identified by observing mass differences in
co-eluting AMRTPS. Na and K adducts were observed as
having mass differences of +22 and +38 respectively
relative to the parent compound mass (M+H). Further-
more, by investigating function 2 fragmentation data,
parent ions were selected as often having reduced peak
intensity compared to Function 1.
Identification of parent ions and AMRTPs
Final selection for parent ions was based on raw data,
not normalized intensity, reducing the chance of includ-
ing normalization induced false positives. AMRTPs with
poorly consistent peak intensity in replicate infections
were also removed. Out of the 16 final parent ions
selected, 4 were removed as being artifacts of the
normalization process. The 12 remaining AMRTP
parent ions were selected for identification using a com-
bination of database searching, spectral matching, elem-
ental composition analysis and in silico fragmentation.
For AMRTP identification function 2 MS/MS data was
screened in Metlin for MS/MS fragmentation patterns.
When available, if MS/MS fragmentation data was
present in the database, MS/MS function 2 data in +ve
or –ve ionization mode was screened for identification.
Elemental composition of the 12 parent compound was
determined in MassLynx. 6 of the 12 compounds chosen
had % confidence fit of the isotope pattern between 90
and 100%. Function 2 fragmentation data was screened
Non-vaccinated
Vaccinated
A B C D
E F G
Figure 4 Unsupervised PCA scores plot of UPLC-MS profiled plasma from vaccinated and non-vaccinated calves. Unsupervised PCA
scores plot of plasma from vaccinated and non-vaccinated calves at days 0, 7, 14, 28, 42, 49 and 63 are illustrated in Figures 4 A-G respectively.
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against the Metlin online database. The retention time
and accurate mass of identified markers of immune
response to vaccination are presented in Table 1 together
with the percentage confidence of elemental composition
determination in addition to potential database IDs.
Of the 12 potential markers identified to differ signifi-
cantly between vaccination study groups, 5 had their
identities confirmed using pure standards (Uric Acid
(UA), Glycocholic Acid (GCA), Taurodeoxycholic Acid
(TDCA), Biliverdin (BLD), Hippuric Acid, (HA) and
Figure 5 S-plots of supervised OPLS-DA analysis of UPLC-MS profiled plasma from vaccinated and non-vaccinated calves. Supervised
OPLS-DA S-plot plots of plasma from vaccinated and non-vaccinated calves at days 7, 14, 42 and 49 are illustrated in Figures 5A-D respectively.
The location of AMRTPs on the S-Plot is a combination of influence (p [1]) and reliability (p(corr) [1]) on the discrimination of study groups by
OPLS-DA. Identified vaccine response markers and AMRPTs selected throughout the study are marked on the S-Plot.
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Hexahydrohippuric Acid (HHA)). Putative identities based
on PubChem database searching and in silico fragmenta-
tion using MetFrag were obtained for propionylcarnitine
(PLC), N-[(3α,5β,12α)-3,12-dihydroxy-7,24-dioxocholan-
24-yl]glycine (NDGCA), N-methylhippuric acid (NMHA)
and N-(cyclohex-1-en-1-ylcarbonyl)glycine (NCG) - iden-
tities for the AMRTPs 0.4295_151.145 and 0.4926_156.105,
could not be assigned. The influence (p[1]) and reliability
(p(corr)[1]) of these markers on the OPLS-DA multivariate
data analysis can be observed in the S-plots illustrated in
Figures 5A-D. AMRTPs with high influence and reliability
are indicated in the top right and bottom left corners of
the S-plots. The variations in detected marker peak
intensities between treatment groups throughout the study
are indicated in Figure 6. These findings indicate that fluc-
tuations in metabolite marker levels can occur throughout
sampling stages due to environmental factors, as illustrated
in the temporal variations apparent in non-vaccinated
control animals. Elevated metabolite levels in vaccinated
animals, as illustrated at day 14 for 0.4926_156.105, NCG,
PLC and HHA, are therefore vaccine induced temporal
increases in these markers which contrasts with the normal
temporal decrease observed in non-vaccinated controls as a
result of environmental factors. HHA and NCG were
shown to differ significantly between study groups at day 0.
Repeated measures ANOVA with bonferroni post-hoc test
revealed significantly different temporal relationships
between study groups day 0 to day 7 with HHA and NCG
found to decrease significantly (p < 0.05) in vaccinated
animals only from day 0 to day 7. Peak intensity of
HHA and NCG differed significantly between treatment
groups at a number of stages, with Pearson correl-
ation showing significant positive correlation (p < 0.001,
r = 0.982 and r = 0.951 in vaccinated and non-vaccinated
animals respectively). Coupled with TDCA these were the
only AMRTPs to differ at the earliest post vaccination
sampling point (day 7), prior to observable difference in
anti-BPI3V IgG titre between study groups. The sig-
nificant up and down regulation of 0.4926_156.105
and NMHA respectively was limited to primary vaccine
dosage, and is likely to be related to the adaptive immune
response to vaccination (significant rise in IgG BPI3V anti-
body titre at day 14). NHMA was found to significantly
decrease (p < 0.05) from day 0 levels in vaccinated animals
at day 14. Significantly higher (p < 0.05) 0.4296_156.105 at
day 14 in vaccinated animal was a result of vaccine
induced deviation from the temporal decrease from day 7
to 14 observed in non-vaccinated control animals.
The remaining identified markers were found to differ
significantly during the phase of secondary immune
response. Peak intensity of UA was significantly higher
(p < 0.05) in vaccinated calves compared to non-vaccinated
calves at day 42 and was significantly higher (p < 0.05) than
day 0 levels in vaccinated animals at days 7, 14 and 28.
GCA was significantly up-regulated in vaccinated calves at
days 42 and 49, however, this was a result of booster
induced deviation in vaccinated animals which differed from
the temporal profile observed in control non-vaccinated
animals. Peak intensities of 0.4295_151.145 and HA were
found to be significantly lower in vaccinated calves at day
49 and significantly lower (p < 0.05 and p < 0.01 respectively)
than day 0 levels in vaccinated animals. BLD and
NDGCA were up-regulated at day 49 in vaccinated
animals, significantly higher (p < 0.05) than day 0 levels.
Furthermore, HHA and NCG levels were found to be
significantly correlated with HA throughout the study
Table 1 Final AMRPTs selected as metabolomic markers of response to vaccination
AMRTP I.D. Retention
time (mins)
Measured
mass (Da)
Elemental
composition (M + H)
% Fit
confidence
Mass Error
(mDa)
PubChem
I.D.
Compound
0.4295_151.145 0.4295 151.145 C6H19N2O2 98.17 0.7 Unknown
0.4926_156.105 0.4926 156.105 C8H14NO2 99.66 1.4 Unknown
0.6158_169.039 0.6158 169.039 C5H5N4O3 99.48 −0.4 1175 Uric Acid (UA)a
1.4952_218.14 1.4952 218.14 C10H20NO4 95.95 −0.2 107738 Propionylcarnitine (PLC)
4.2427_180.066 4.2427 180.066 C9H10NO3 74.69 1.1 464 Hippuric Acid (HA) a
4.5993_194.082 4.5993 194.082 C10H12NO3 54.33 −1.1 97479 N-Methylhippuric Acid (NMHA)
4.8821_184.097 4.8821 184.097 C9H14NO3 34.64 −0.2 149048 N-(Cyclohex-1-en-1-ylcarbonyl)glycine
(NCG)
5.006_186.113 5.006 186.113 C9H16NO3 100 0.1 147412 Hexahydrohippuric Acid (HHA)a
7.1759_464.3 7.1759 464.3 C26H42NO6 96.92 −0.6 10253857 N-[(3α,5β,12α)-3,12-Dihydroxy-7,
24-dioxocholan-24-yl]glycine (NDGCA)
7.7341_466.317 7.7341 466.317 C26H44NO6 16.22 −0.6 10140 Glycocholic Acid (GCA)a
8.2088_500.304 8.2088 500.304 C26H46NO6S 5.8 −0.8 44688 Taurodeoxycholic Acid (TDCA)a
8.5105_583.255 8.5105 583.255 C33H35N4O6 18.33 1.4 5280353 Biliverdin (BLD)a
Elemental composition of AMPRTs was calculated in MassLynx, with mass error of 3mDa, and elements C, H, O, P, S and N and % fit confidence for 3 isotopic peaks was
calculated. Where possible spectral match score against function 2 data in Metlin is indicated. Compounds identified by pure standards are indicated witha.
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in vaccinated and non-vaccinated animals (HHA and
HA, p < 0.001, r = 0.971 in vaccinated animals and p < 0.01
and r = 0.894 in non-vaccinated animals; NCG and
HA, p < 0.01, r = 0.917 in vaccinated animals and p < 0.05,
r = 0.761 in non-vaccinated animals).
Discussion
Vaccine development strategies have typically focused
on the induction of specific antibody responses to anti-
genic molecules as an indicator of effective immune
stimulation (whole virus or viral proteins) with little
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Figure 6 Temporal changes in metabolite peak intensity throughout vaccination program. Raw peak intensity (height) of the selected
biomarkers at each sampling stage is indicated (n = 6). Significant changes in metabolite peak intensity between vaccinated and non-vaccinated
calves at the corresponding study day (height) are indicated *P < 0.05, **p < 0.01, ***p < 0.001. Values represent mean ± S.E.M, n = 6.
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understanding of how antigens elicit particular immune
responses [6]. Whilst this approach has resulted in the
majority of vaccines available today, new vaccine devel-
opment is increasingly costly and it is imperative that
the least promising candidates are eliminated from
investigation as early as possible. Whilst the identifica-
tion of immune correlations, in particular proteins such
as interleukins and cytokines, has helped to improve the
understanding of vaccine mediated immune response
mechanisms, emerging metabolomic techniques may
offer a novel perspective to vaccine development and
selection. This is possible as metabolites are the ultimate
end stage products or mediators of biological processes
and can provide a holistic view of underlying physiological
processes. This study has for the first time employed an
untargeted UPLC-MS metabolomic profiling approach to
identify plasma components altered by primary and
secondary immune responses to an intranasal vaccination
containing live modified virus. Vaccination with Pfizer
Rispoval® PI3 + RSV resulted in an increase of BPI3V
specific IgG antibody titre in vaccinated calves. The IgG
responses indicated that the booster immunization was
necessary to further increase the titres of BPI3V antibodies.
This stimulated IgG response is characteristic of the
immune responses typically seen in two dosage vaccination
experiments. Furthermore, the high IgG titre maintained
in vaccinated animals following experimental challenge
with BPI3V indicates a primed immune response to infec-
tion. Conversely the non-vaccinated animals showed no
significant alterations in BPI3V specific IgG titre during
vaccination stages but at post-BPI3V challenge displayed
a rise in WCC indicating a stimulated immune response
in the absence of prior infection. We can therefore
characterize the markers identified in this study which
showed altered abundance between vaccinated and
non-vaccinated study groups as being related to the
immunological responses involved in primary and second-
ary immune-stimulation. Metabolomic profiling initially
revealed a panel of 96 features which differed significantly
between calves vaccinated intranasally with Pfizer
Rispoval® PI3 + RSV and non-vaccinated calves throughout
the study. These features were further refined to identify
12 high confidence parent compounds, 10 of which were
identified based on database searching and spectral
matching, with 6 further validated using pure standards.
Based on the observed stimulated IgG response following
two intranasal vaccine dosages (characteristic of the
immune response typically seen in two-stage dosage
vaccine programs [6]), these markers can be characterized
as being related to the responses involved in primary and
secondary immune stimulation. All detected markers
were shown to be present in plasma prior to vaccine
administration, therefore their altered abundance reflects
the processes of stimulation of the mucosal immune
system following exposure of animals to modified live viral
vaccine, and are not associated with vaccine breakdown
products.
A significant increase in BLD (10.26 FC) plasma
peak intensity in vaccinated calves compared to non-
vaccinated calves was observed two weeks after the
second Pfizer Rispoval® PI3 + RSV dosage (day 49).
BLD is degraded from heme groups by Heme Oxygenases
(HO) [25] and rapidly reduced to Bilirubin by Biliverdin
Reductase [26]. BLD and the HO isoform HO-1 are
involved in promoting anti-inflammatory responses. BLD
suppresses IL-2 production and T cell proliferation
[27], and activates the aryl hydrocarbon receptor
(AHR) [28] regulating T helper cell phenotype towards an
anti-inflammatory regulatory T cell, or a pro-inflammatory
T helper 17 effector function [29,30]. HO-1, produced
from circulating monocytes during acute inflammatory
states, has immunomodulatory function by supporting the
proliferative capacity and activation of CD4(+) and CD8(+)
T cells via CD14(+) monocytes, preventing DC maturation
[31-33] and controlling Th1 pro-inflammatory cytokine
production [34,35]. The observed increased plasma levels
of BLD may be due to either increased HO-1 activity at a
rate which cannot be matched by Biliverdin Reductase, or
an unknown modulatory effect on Biliverdin Reductase
affecting the rate at which it reduces BLD to bilirubin -
strongly supporting BLD and HO-1 involvement in
the promotion of anti-inflammatory responses as the
immune stimulation response following vaccine dosage is
deactivated to normal status.
Plasma peak intensities of a number of conjugated Bile
Acids (BAs) were found to differ significantly between
vaccinated and non-vaccinated calves, with increased
TDCA (4.87 FC) after primary vaccine dosage (day 7,
prior to observable differences in IgG titre) and increased
GCA (1.63 and 2.12 FC) and NDGCA (1.80 and 3.29 FC)
after secondary dosage (day 42 and 49 respectively) in
vaccinated animals. The up-regulation of different BA
conjugates at different stages following vaccination
suggests that Cholic acid conjugation may allow for
mediation of different immune response pathways,
dependent on the amino acid that is conjugated. To
date the only other published study assessing metabolomic
responses to vaccination reported an up-regulation of
serum cholesterol levels at days 5 and 10 in rabbits after
primary and secondary immunization (using human red
blood cells) respectively [1]. As cholesterol is a precursor to
Cholic acid, and hence GCA and TDCA, it’s up-regulation
could be due to an increased demand for immuno-
regulatory BAs. BAs have recently been demonstrated
to function as signaling molecules with immunomod-
ulatory effects resulting from their activation of the
nuclear receptor Farsenoid X Receptor (FXR) [36,37]
and the G-protein coupled receptors Transmembrane G
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protein coupled receptor 5 (TGR5) [38,39] and the Formyl-
peptide receptors (FPR) [40]. TGR5, present in a variety of
cells of the immune system including alveolar macrophages
and dendritic cells [38,41], can be activated by BAs
to stimulate cAMP production which inhibits pro-
inflammatory cytokines secretion (TNF-α, IL-1β, IL-1α,
IL-6 and IL-8) [38]. This activation favours more
hydrophobic BAs [38], with TDCA more likely to
activate TGR5 in vivo compared to GCA or NDGCA
and its’ up-regulation at day 7 in vaccinated calves
illustrates a potential role in arresting innate inflam-
matory response in favour of the progression of adap-
tive immunity through the activation of TGR5.
Dendritic cells demonstrate FXR modulated function
following BA treatment, resulting in increased production
of IFN-γ producing T-cells and reduced airway eosinophilia
and macrophage influx after OVA airway stimulation [42].
Activation of FXR by synthetic bile acid ligands also results
in NK T-cell inhibition and reduced pro-inflammatory
osteopontin production which indicates FXRs role in
maintaining immune homeostasis [43]. Both TDCA
and GCA have been shown to activate FXR in vivo,
upon transportation into FXR expressing cells [44].
However, the consequences of BA driven FXR modulation
would favour an adaptive immune response, which would
therefore be associated with secondary booster dosage
stages where increased plasma levels of GCA and
NDGCA were observed in vaccinated animals. Significant
up-regulation of circulating plasma levels of GCA could
provide a method by which pro-inflammatory responses
at the site of infection are limited after secondary exposure
to viral infections. GCA induced activation of FXR at
post-booster stages in vaccinated animals may reduce
macrophage and neutrophil influx to the site of infection
and increase the levels of INF-γ producing CD4+ and
CD8+ T-cells, promoting an adaptive immune response.
Significantly higher levels of PLC (2.21 FC) in vaccinated
relative to non-vaccinated calves were observed at day 14
post initial vaccine dosage, suggesting a potential role of
PLC in either mediating adaptive immune responses
following primary immune stimulation, or as an end-stage
metabolite produced as a result of these processes. PLC
has been demonstrated to modulate innate immune
response following transplantation by preventing neutro-
phil, CD4+, CD8+, ED1+ and MHCII cell infiltration upon
transplantation, protecting grafts from oxidative stress
injury [45]. In vivo PLC treatment resulted in significant
decrease in the release of leukocyte adhesion molecules
into plasma (E-selectin, P-selectin, L-selectin ICAM-1 and
VCAM-1) [46] suggesting PLC’s action in modulating
leukocyte function and trafficking, with a potential role in
reducing immune cell recruitment to sites of active viral
replication with the progression of adaptive immunity
associated with increased BPI3V IgG production at day 14
in this study. The immunomodulatory effects of PLC are
further demonstrated by its’ potential to reduce platelet
activating factors when exposed to neutrophils in vitro
and in vivo [47]. The significant up-regulation of PLC at
day 14 may therefore be due to its’ anti-inflammatory
effect in arresting pro-inflammatory leukocyte recruitment
in favour of adaptive immune response.
UA released from injured cells activates the NALP3
inflammasome leading to IL-1β production [48], but
the specific mechanism by which UA promotes its
immunosuppressive effects is not fully understood
[49,50]. Significantly higher levels of UA (1.57 FC) were
observed in vaccinated relative to non-vaccinated calves at
day 42 (1 week post second vaccine dosage) and would
suggest an increased population of cytotoxic T cells
responding to re-exposure to the live attenuated vaccine.
Whilst there has been no previously reported evidence of
the direct immunosuppressive properties of HA or HHA,
significantly lower levels of HA (21.70 FC) were observed
in vaccinated animals at day 49 (2 weeks post booster
immunization), and significant differences in the plasma
peak intensity of HHA in vaccinated animals compared to
non-vaccinated at days 7 (−1.82 FC), 14 (4.45 FC) post
initial immunization and days 42 (1.63 FC), 49 (− 3.41 FC)
and 63 (2.17 FC), 1, 2 and 4 weeks post booster
immunization respectively. Reduced plasma HA levels in
vaccinated calves compared to non-vaccinated calves,
suggests that it does not exert a direct anti-inflammatory
effect. HA may instead be involved in the mediation of
immune response through its’ metabolism to produce
compounds which exert a direct immuno-modulatory
effect. Hippuric acid is an acyl-glycine, formed through
the action of N-acyltransferase involving Acyl-CoA.
Circulating HA in mammals is primarily derived from
the metabolism and glycine conjugation of phenolic
dietary constituents [51]. The metabolites HHA, NMHA
and NCG have acyl-glycine like fragmentation patterns,
with HHA and NCG levels found to significantly correlate
with HA. As dietary composition was consistent between
study groups and significant variation in HA occurred
only at post-booster stages, the reduced plasma HA levels
may result from reduced N-acyltransferase activity (due
to increased metabolic demand for acyl-CoA) coinciding
with a marked reduction in plasma levels of other
metabolites (HHA and NCG).
In conclusion, this study has demonstrated the ability
of untargeted UPLC-MS metabolomics to differentiate
between vaccinated and non-vaccinated animals via the
profiling of metabolite constituents in plasma. A number
of plasma constituents were found to be associated with
initial and/or booster vaccine dosage events and were
therefore characterized as corresponding to primary
and/or secondary immune stimulation. The markers
associated with primary immune stimulation to vaccine
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administration, particularly TDCA and HHA which varied
in plasma prior to observable variations in BPI3V IgG, may
find application as early diagnostic markers to screen for
immunogenic candidates during vaccine selection investi-
gations, particularly for vaccines targeting routes of patho-
gen entry such as through the respiratory tract. The
metabolites GCA, NDGCA, UA and BLD, which were
altered within plasma at the secondary vaccine dosage
stages, may additionally represent key diagnostic markers
of established immune protection in animals. A number of
the selected markers have demonstrated immunological
properties, affecting key cell signaling pathways and recep-
tors located on cells of the immune system. Further valid-
ation studies are required to expand upon this initial proof
of concept study to discern whether the differences
observed in these metabolite marker levels as a result of
vaccination are repeatable in a larger external sample set
comprising animals of varying ages, genders and breeds
coupled with more frequent sampling. However, this
study’s findings illustrate the potential for untargeted meta-
bolomics to identify key metabolite immune correlates
which relate to specific cell signaling pathways involved in
immune responses. The assessment of such metabolite
markers may provide greater information on the immune
pathways stimulated (compared to traditional IgG or IgA
serology) by vaccine formulations, and in particular
benchmarking early metabolomic responses to highly
immunogenic vaccine formulations could provide a means
of rapidly assessing new vaccine candidates. Furthermore,
a greater understanding of the metabolite pathways altered
as a result of vaccination could allow for targeted vaccine
design (antigens, adjuvants and nanoparticle carrier
systems) to stimulate key immunogenic pathways which
can be assessed at the metabolite level. Currently, metabo-
lomics does not lend itself easily to routine vaccine candi-
date screening, due to the requirement of costly analytical
equipment and skilled operators. However, recent advances
in portable mass-spectrometers, such as the 908 Devices
handheld system (908 Devices, Boston, USA), or the more
user friendly Microsaic 4000 MiD® (Microsaic Systems,
Surrey, UK), may eventually see the use of metabolites as
routine markers for the evaluation of vaccine candidate
immune function and immunogenicity. Future research
will seek to expand upon the physiological role of these
metabolomic markers and focus on establishing the
biological pathways in which they may play a role in
immuno-modulatory activities.
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models and the remaining 1/3 as a test set.
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of response to vaccination. Combined list of markers selected using
OPLS-DA at days 7, 14, 42 and 49 and filtered to exclude those with
p < 0.05, FC < 1.5 and V.I.P. score < 1.
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